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Extracellular High Mobility Group Box 1 (HMGB1) has been associated with acute
and chronic inflammatory conditions. However, little is known about HMGB1 in
necrotizing bacterial infections. We hypothesized that the local HMGB1 response is
excessive in severe soft tissue infections (STIs), which are characterized by necrosis and
hyperinflammation. To explore this, tissue biopsies were collected from patients with
varying severity of Streptococcus pyogenes skin and STIs, including erysipelas, cellulitis,
and necrotizing fasciitis. Tissue sections were immunostained for HMGB1, S. pyogenes,
and inflammatory cell infiltrates and results quantified by acquired computerized image
analysis (ACIA). HMGB1 expression increased in parallel to disease severity and was
significantly higher in necrotizing fasciitis than in erysipelas (p = 0.0023). Confocal
microscopy of sections co-stained for HMGB1 and cell markers revealed both extracellular
and cytoplasmic HMGB1, the latter of which was found predominantly in macrophages. To
further verify macrophages as main source of activation triggered HMGB1 release, human
macrophages were infected with clinical S. pyogenes isolates. The results demonstrated
infection triggered release of HMGB1. Dual staining’s visualized HMGB1 in areas close
to, but not overlapping, with neutrophils, indicating a potential chemotactic role. In vitro
transmigration experiments showed a chemotactic effect of HMGB1 on neutrophils. The
data furthermore provided in vivo support that HGMB1 may form immunostimulatory
complexes with IL-1β. Taken together, the findings provide the first in vivo evidence that
HMGB1 is abundant at the local site of severe bacterial STIs and its levels correlated
to severity of infections; hence, indicating its potential value as a biomarker for tissue
pathology.
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INTRODUCTION
High mobility group box protein 1 (HMGB1) is a ubiquitously
expressed, highly conserved nuclear protein that is released either
through active secretion by innate immune cells, enterocytes and
hepatocytes or through passive release by injured, autophagic or
necrotic cells (Bianchi et al., 1989; Tsung et al., 2007; Livesey et al.,
2009; Skinner, 2010; Tang et al., 2010; Thomas and Stott, 2012).
Extracellular HMGB1 has been reported to act as an alarmin with
ability to activate the immune system leading to cell proliferation,
adhesion, migration, and cytokine release (Harris et al., 2012).
Several receptors have been shown to interact with HMGB1
including toll-like receptor 4 (TLR4), the receptor for advanced
glycation end products (RAGE) and CD24-Siglec-10 (Lotze and
Tracey, 2005; Tian et al., 2007; Chen et al., 2009). Studies have
suggested differential responses depending on receptor engage-
ment, with TLR4 being involved in cytokine release (Yang et al.,
2010) whereas RAGE is involved in cell migration (Penzo et al.,
2010). Importantly post-translational modifications, including
acetylation, phosphorylation, methylation and redox state of the
cysteine residues, influence receptor interactions, and thereby,
elicited responses (Harris et al., 2012; Venereau et al., 2012; Yang
et al., 2012).
HMGB1 has been implicated in a variety of clinical condi-
tions including arthritis, sepsis and chronic kidney disease (Harris
et al., 2012). In sepsis, murine experimental data demonstrated a
critical role of HMGB1 as a late mediator contributing to mortal-
ity (Wang et al., 1999). Subsequently, elevated levels of HMGB1
have been readily detectable in circulation of patients with severe
sepsis and septic shock (Sunden-Cullberg et al., 2005). However,
little is known about local HMGB1 responses in acute necrotic
bacterial soft tissue infections (STIs), such as necrotizing fasci-
itis. These are life-threatening infections where the vast majority
of patients require intensive care and extensive surgical interven-
tions. Despite modern medicine, the mortality associated with
necrotizing soft tissue infections (NSTIs) is high, often exceeding
30% (Anaya et al., 2005; Marwick et al., 2011). Although a num-
ber of bacteria can cause NSTI, the main causative microbes are
Streptococcus pyogenes and Staphylococcus aureus (McHenry et al.,
1995). Here we set out to gain insight into events occurring in
the microenvironment at the infected tissue site by delineating
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HMGB1 responses in acute necrotic STIs caused by Streptococcus
pyogenes. Analyses of tissue biopsies from patients with varying
severity of S. pyogenes infections revealed a significant correlation
between increased HMGB1 and severity of tissue infection.
MATERIALS AND METHODS
PATIENT MATERIAL
The biopsy material from severe streptococcal infections has
been described previously in (Thulin et al., 2006). The material
included snap-frozen tissue biopsies (n = 25) collected from six
patients with necrotizing fasciitis (n = 22) or cellulitis (n = 3),
caused by S. pyogenes of varying serotypes (Table 1). Biopsies
received a clinical grade at the time of sampling (grade 1: dis-
tal tissue not visually inflamed; n = 5, grade 2: inflamed tissue
including cellulitis, fasciitis, and necrotizing fasciitis; n = 20)
(Thulin et al., 2006). Snap-frozen punch biopsies collected from
patients with erysipelas (n = 11) were also included (Linder et al.,
2010).
Plasma samples collected at admission from patients with
Streptococcal Toxic Shock Syndrome (STSS) were included
(n = 14) (Darenberg et al., 2003) as well as plasma samples from
14 healthy volunteers (controls).
All samples were obtained from the patients after written
informed consent and from healthy volunteers, according to pro-
tocols approved by the ethics committee at respective University
and in accordance with the Declaration of Helsinki Principles.
IMMUNOSTAININGS OF TISSUE BIOPSY SPECIMEN
Biopsies were cryosectioned (8μm), fixed in 2% formaldehyde
and immunostained as previously described (Norrby-Teglund
et al., 2001; Thulin et al., 2006; Johansson et al., 2009). The
immunohistochemical staining was modified to include an ini-
tial blocking step with 10% FCS in Earl’s balanced salt solution
and 0.1% saponin at room temperature for 30min. The brown
color reaction was developed by diaminobenzidine (DAB-kit
from Vector Lab Inc.). The staining pattern of HMGB1 in the
biopsies revealed both intracellular and extracellular HMGB1;
however, not all cells stained positive despite the fact that this is a
nuclear factor. This has also been noted by others (Ulfgren et al.,
2004), and is likely due to technical limitations in identification of
nuclear HMGB1, potentially through insufficient antibody access
to the nuclei. The immunohistochemically stained sections were
analyzed by acquired computerized image analysis (ACIA), which
has proven to be a robust method for semiquantitative assessment
of cell infiltrates and inflammatory markers in single cells and tis-
sue (Norrby-Teglund et al., 2001; Thulin et al., 2006; Johansson
et al., 2008). Analyzed cell area (defined by the haematoxylin
counterstaining) ranged from 0.2 × 105 to 7.9 × 105 μm2 for
deep tissue biopsies and 9.6 × 105 to 7 × 106 μm2 for erysipelas
biopsies. The results are presented as ACIA value, i.e., percent
positively stained area × mean intensity of positive staining.
Single and dual immunofluorescence stainings were per-
formed as previously described (Thulin et al., 2006) and visu-
alized using either a Leica confocal scanner TCS2 AOBS with
an inverted Leica DMIRE2 microscope (Wetzlar, Germany)
or a Nikon A1R confocal microscope (Nikon Instruments,
Amstelveen, the Netherlands).
Table 1 | Characteristics of tissue biopsy material.
Patient ID Diagnosis GAS serotype Day of Type of tissue
samplinga














8489 STSS/NF M1 1 Fascia
1 Muscle
4 Subcutaneous
8157 STSS/NF M1 3 Muscle
9 Muscle/fascia
5626 NF M3 1 Muscle
3 Muscle
6 Fascia
8271 Cellulitis M1 1 Subcutaneous
3 Muscle
3 Muscle
1 Erysipelas n.a. 3 Skin
3 Erysipelas n.a. 2 Skin
4 Erysipelas n.a. 2 Skin
5 Erysipelas n.a. 1 Skin
6 Erysipelas n.a. 2 Skin
7 Erysipelas n.a. 3 Skin
8 Erysipelas n.a. 1 Skin
9 Erysipelas n.a. 3 Skin
10 Erysipelas n.a. 1 Skin
11 Erysipelas n.a. 2 Skin
12 Erysipelas n.a. 2 Skin
GAS, Group A Streptococcus; STSS, streptococcal toxic shock syndrome; NF,
necrotizing fasciitis; n.a., not available.
aAfter onset of diagnosis.
The following antibodies were used: anti-CD68, anti-
neutrophil elastase, anti-mast cell tryptase (DAKO, Glostrup,
Denmark), biotinylated anti-IL-1β/IL-1F2, anti-CXCL12 (R&D
systems, Minneapolis, MN), and anti-CD1a (BD Biosciences
Pharmingen, San Diego, CA). HMGB1 was initially identi-
fied using a polyclonal anti-HMGB1 from BD Biosciences
Pharmingen (556528, BD Diagnostics, San Diego, CA) or
anti-human HMGB1 (ab18256, Abcam, Cambridge, UK).
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Streptococcus pyogenes were identified with a polyclonal rabbit
antiserum specific for the Lancefield group A carbohydrate
(Difco, BD Diagnostics, Sparks MD). Biotinylated secondary
antibodies included goat-anti-mouse IgG and goat-anti-mouse
IgG (both from Vector Laboratories, Burlingame, CA).
BACTERIAL STRAINS
Two clinical M3 isolates of S. pyogenes, obtained during the col-
lection of the Canadian patient material described above, were
grown over night (16–18 h) in Todd-Hewitt broth complemented
with 1.5% yeast extract. A clinical isolate of Escherichia coli,
obtained from a sepsis patient, was also included in the study and
was grown over night in Luria Broth medium. Before infection
the bacterial cultures were centrifuged at 2500 rpm for 10min
and resuspended in RPMI 1640 cell culture medium supple-
mented with 5% heat inactivated FCS, 10mM L-glutamine, and
25mmol/L HEPES (all from Thermo Scientific, Hyclone).
INFECTION OF PRIMARY HUMANMONOCYTE-DERIVED
MACROPHAGES
Human monocyte-derived macrophages were isolated form
healthy blood donors using RosetteSep (Stemcell Technology)
and Lymphoprep (Axis-Shield) gradient centrifugation, as pre-
viously described (Hertzen et al., 2010). After isolation, the
isolated cells were resuspended in RPMI 1640 cell culture
medium supplemented with 5% heat inactivated FCS, 10mM
L-glutamine, Penicillin (100U/ml)/Streptomycin (100 ug/ml)
solution, and 25mmol/L HEPES (all from Thermo Scientific,
Hyclone) as well as 50 ng/ml of Macrophage colony stimulat-
ing factor (Immunotools). Cells were seeded at a concentration
of 1 × 106 cells/ml in 6-well low adherence tissue culture plates
(Corning) and cultured for 7–8 days to obtain macrophages. At
day 8 cells were washed with phosphate buffered saline (PBS;
Sigma-Aldrich, St Louis, MO), harvested and resuspended in
RPMI 1640 cell culture medium supplemented with 5% heat
inactivated FCS, 10mM L-glutamine and 25mmol/L HEPES.
Cells were seeded in 24-well tissue culture plate, containing a ster-
ile coverslip at the bottom of each well, at a concentration of
1 × 106 cells/ml and incubated over night at 37◦C with 5% CO2.
Cells were then infected with S. pyogenes or E. coli, at a multi-
plicity of infection (MOI) of 1–11 bacteria per cell. Four hours
post infection cell culture supernatants were collected and cen-
trifuged at 2500 rpm for 10min, aliquoted and stored at −20◦C.
The cells, situated on coverslips were fixed with 2% paraformalde-
hyde for 15min at room temperature. After fixation, cells were
washed with PBS, dried and stored at −20◦C.
HMGB-1 ELISA
HMGB-1 was measured by ELISA (Shino-Test Corporation,
Tokyo, Japan) according to manufacturer’s instructions. The
range of detection was 2.5–80 ng/ml. All samples were analyzed
in duplicates.
IL-8 LUMINEX
Plasma level of IL-8 was determined by Luminex IL8 human sin-
gleplex bead kit (Invitrogen, Paisley, UK), and the Luminex (100)
instrument (Luminex, Invitrogen, Paisley, UK). All samples were
analyzed in duplicate.
WESTERN BLOT
The positive control recombinant HMGB1 (provided in dithio-
threitol (DTT); R&D Systems, Minneapolis, MN) and tissue
biopsies (n = 2) (12 sections, 8μm thick) suspended in PBS were
incubated with NuPAGE SDS loading buffer (Life Technologies,
Carlsbad, CA) at 90◦C for 15 or 25min, respectively. Proteins
were separated using a 12% NuPAGE Novex Bis-Tris gel (Life
Technologies, Carlsbad, CA) and transferred onto nitrocellulose
membrane using the iBlot system (Life Technologies, Carlsbad,
CA). The membrane was blocked using 5% dry milk powder and
0.1% Tween-20 PBS saline. HMGB1 was detected using an anti-
HMGB1 antibody (Sigma Aldrich, St. Louis, MO) in combination
with a horseradish-peroxidase labeled anti-mouse antibody (GE
Healthcare, Little Chalfont, UK), and an electrochemilumines-
cence kit (Thermo Scientific, Waltham, MA). Both the oxidized
or reduced forms of HMGB1 were detected under these condi-
tions in sizes corresponding to that reported previously (Venereau
et al., 2012). It should be noted that the recombinant protein has a
molecular weight of 24.9 kDa but separates as a 30–36 kDa protein
in SDS-PAGE according to the manufacturer’s specification.
CHEMOTAXIS ASSAY
Chemotactic effect of HMGB1 was measured using a transwell-
based assay as detailed in Berthelot et al. (2012). Whole-blood
was chosen as a previous report showed that neutrophil isola-
tion methods might affect cell motility (Sroka et al., 2009). In
short, 600μl of PBS with 1% human serum and recombinant
HMGB1 or IL8 (R&D Systems, Minneapolis, MN; both supplied
in preparations with endotoxin levels <1 EU/μg) was added to
the basolateral side of a 3μm pore-size polycarbonate transwell
membrane (Coring incorporated, Corning, NY). One hundred
microliters of human whole blood diluted 1/10 in PBS was added
to the membranes apical side, and cells left to migrate for 2 h in
37◦C. Migrated cells were collected and stained with anti-human
CD14 PE and anti-human CD15 FITC (BD Bioscience, San Jose,
CA). The number of migrated neutrophils was determined using
a BD LSRII Fortessa cell analyser (BD Bioscience, San Jose,
CA) in combination with CountBright Absolute Counting Beads
(Molecular Probes Inc., Eugene, OR), and analyzed using the
FlowJo software version 9.5.3 (Tree Star, Ashland, OR).
RESULTS
LEVEL OF HMGB1 RESPONSE CORRELATES TO SEVERITY OF
S.PYOGENES TISSUE INFECTIONS
First we sought to determine the presence of HMGB1 at the
local tissue site in S. pyogenes infected patients. To this end, a
tissue material collected from patients with varying severity of
streptococcal tissue infections, i.e., mild erysipelas (n = 11), to
more severe STIs including severe cellulitis and necrotizing fasci-
itis (n = 6) (Table 1), were immuno-histochemically stained for
HMGB1, bacterial load, and inflammatory cells. Stainings were
evaluated by microscopy and in situ image analysis. HMGB1 was
detected in all analyzed biopsies (11 erysipelas and 25 severe STIs)
and demonstrated both a diffuse, supposedly secreted HMGB1,
as well as distinct intracellular staining (evident in some but not
all cells) (Figures 1A,B). In agreement with our previous publica-
tion (Thulin et al., 2006), in severe STIs all biopsies displayed high
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FIGURE 1 | HMGB1 at the local site of infection. Snap-frozen tissue
biopsies (n = 25) from patients with severe soft tissue infections caused by
S. pyogenes were immunohistochemically stained for S. pyogenes,
macrophages identified by CD68-positivity, neutrophils identified by
neutrophil elastase positivity, and HMGB1. A control staining where the
primary antibody was omitted was also performed (control). (A)
Representative immunohistochemically stained biopsies taken from the site
of infection at day 1 from two patients (patient 8271, top panel, and patient
8611, bottom panel) (Table 1). Positive stainings for cell markers and for
HMGB1 are indicated by a brown color, and all cellular nuclei are stained blue
by haematoxylin. Bars indicate 50μm. (B) Staining’s for HMGB1 revealed
both a diffuse (top picture, indicated by white stars) and a distinct intracellular
staining (bottom picture, indicated by the black arrow). Bars indicate 50μm.
(C) Image analysis values for S. pyogenes, macrophages (CD68), neutrophils
(NE), and HMGB1 in the different biopsies were obtained by ACIA; for details
see Materials and Methods. The horizontal lines denote median.
bacterial burden and heavy infiltration of both macrophages and
neutrophils (Figures 1A,C). Although HMGB1 was commonly
found in the areas with dense bacteria load and inflammatory
cell infiltrates (Figure 1A), neither bacterial load, nor phago-
cytic cellular infiltration correlated significantly with amount of
HMGB1 (data not shown). It seems likely that this lack of associ-
ation might be due to the lack of tissue integrity caused by the
high degree of necrosis present in severe STI biopsies. In fact
in erysipelas where no necrosis is present, HMGB1 significantly
correlated with the neutrophil infiltration (r = 0.78; p = 0.0064)
(Figure 2A), but not with macrophage infiltration or bacterial
load (data not shown). The latter is not surprising as the bacte-
rial load is substantially lower in erysipelas than in severe STIs
(Linder et al., 2010).
Importantly, semiquantitative assessment of HMGB1 at the
infected site in patients with erysipelas compared to severe STIs
revealed an increase in parallel to disease severity (p = 0.0023)
(Figure 2B). The lowest values were noted in erysipelas biop-
sies, followed by biopsies from severe STIs taken in distal visually
not inflamed areas, and the highest were found at the center of
infection in biopsies from STI (Figure 2B). Similarly, analyses
of biopsies taken from a patient with erysipelas at the cen-
ter of infection, distal (5 cm outside the lesion) and healthy
region (other non-infected leg) demonstrated that both HMGB1
and bacterial load increased with more involved inflamed tissue
(Figures 2C,D).
This marked local HMGB1 response led us to explore sys-
temic HMGB1 levels in a cohort of patients with the most severe
manifestation of invasive S. pyogenes infections, namely STSS.
Plasma levels of HMGB1 were measured at the day of inclu-
sion. Significantly elevated levels of HMGB1 were detected in
patients as compared to healthy controls (Figure 3A, p = 0.0001).
For comparison, all STSS samples were also analyzed for IL-8,
a commonly used marker for systemic inflammation. A signifi-
cant correlation was found between the two markers (r = 0.82;
p < 0.0001) (Figure 3B).
HMGB1 IN RELATION TO INFLAMMATORY CELLS AND INNATE
IMMUNE FACTORS IN VIVO AND IN VITRO
To further characterize HMGB1 at the local site of infection in
relation to inflammatory cells dual immunofluorescence stainings
were performed, using anti-HMGB1 combined with antibod-
ies against various cell markers, including CD68 (macrophages),
neutrophil elastase, mast cell tryptase, and CD1a (Langerhans
cells). In both erysipelas and severe STI, confocal microscopy
analyses revealed that HMGB1 in tissue cells display a characteris-
tic vesicular staining pattern (Figures 4A,D); a pattern consistent
with active nuclear translocation of HMGB1 to the cytoplasm
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FIGURE 2 | HMGB1 correlates with severity of infection. Snap-frozen
tissue biopsies (n = 11) from patients with erysipelas were
immunohistochemically stained for S. pyogenes, neutrophils identified by
neutrophil elastase positivity and HMGB1. (A) Correlation between
neutrophil infiltration in relation to HMGB1 ACIA value (for details see
Materials and Methods) in erysipelas biopsies. Significant correlation, as
determined by Pearson’s correlation test, is indicated by p- and r -values.
(B) Image analysis data of HMGB1 in tissue from patients with
erysipelas were compared with biopsies from patients with severe
streptococcal soft tissue infection of clinical grade 1 and 2 (for details
see Materials and Methods). Statistically significant differences were
determined by 1way ANOVA, Kruskal-Wallis; p = 0.0023. (C)
Representative immunohistochemical pictures of erysipelas tissue
biopsies collected at the inflamed center, 5 cm outside the lesion and
from the healthy leg. Bars indicate 50μm. (D) Acquired computerized
image analysis values of the whole tissue biopsy.
FIGURE 3 | Elevated HMGB1 in circulation in patients with STSS.
HMGB1 and IL-8 levels in plasma collected on the day of inclusion were
measured with ELISA and Luminex respectively, for details see Materials
and Methods. Shown in (A) is systemic HMGB1 in STSS patients (n = 19)
and healthy controls (n = 14). Statistically significant differences were
determined by two-tailed t-test; p = 0.0001. Shown in (B) is systemic
HMGB1 and IL-8 in patients with STSS (n = 19 patients). Significant
correlation, as determined by Pearson’s correlation test, indicated by p- and
r- values.
(Gardella et al., 2002). Importantly, the only two cell types in
the tissue that demonstrated this intracellular HMGB1 were
macrophages (Figure 4A) and mast cells (Figure 4B). The latter
of which constituted only a minor part of the HMGB1 positive
population, due to the low frequency of mast cells in skin and
soft tissue. Thus, the data demonstrates that macrophages are
the major source of active released HMGB1 at the infected tissue
site. To further support this finding, human monocyte-derived
macrophages were infected with two different clinical strains of
S. pyogenes for 4 h. The levels of HMGB1 in the cell supernatant
were measured with an ELISA. HMGB1 was readily detected
in the culture medium of infected macrophages compared with
non-infected macrophages (Figure 4C).
Co-staining of neutrophils and HMGB1 revealed that the
neutrophils were present in areas of HMGB1, but not co-
localizing with HMGB1. In fact, in some areas neutrophil infil-
trates were found to surround HMGB1 positive cell populations
(Figure 4D). As previous studies have attributed the chemotac-
tic activity to the redox state of HMGB1 (Harris et al., 2012),
we next sought to determine the form of HMGB1 in the tissue.
Therefore, protein extracts of tissue biopsy sections were sepa-
rated on a SDS-PAGE gel under non-reducing conditions and
analyzed by Western blot. Detection of HMGB1 in tissue sec-
tions revealed two bands with a similar size and shift that was
previously reported corresponding to the reduced chemotactic
all-thiol-HMGB1 and the pro-inflammatory disulfide-HMGB1
(Figure 4E) (Venereau et al., 2012). The effect of HMGB1 on
neutrophil motility was tested in a human whole-blood transwell
migration assay using different concentrations of HMGB1. Both
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FIGURE 4 | Cellular source of HMGB1 at the site of infection and
chemotactic effect of HMGB1 on neutrophils. The images depicts a
representative cryosections of tissue biopsies from patients with
erysipelas, immunofluorescently stained for (A,B,D) HMGB1 (green) in
combination with (A) macrophages (red) identified by CD68-positivity, (B)
mast cells tryptase, or (D) neutrophils (red) identified by neutrophil
elastase. Note the granular staining of HMGB1 (A,D). Cell nuclei are
stained blue with DAPI. Bars indicate 10μm (A) and 20μm (B,D). (C)
Human monocyte-derived macrophages were isolated from healthy blood
donors and infected with S. pyogenes or E. coli at an MOI of 1–11 for 4 h.
Supernatants were collected and analyzed for HMGB1 using an ELISA.
Uninfected macrophages were used as control. The graph shows the
results obtained from two different donors. (E) Western blot of
recombinant HMGB1 and protein extracts from patient tissue biopsies
(patient 5626 and 8612). Proteins were separated using a 12% NuPAGE
Bis-Tris gel and visualized using a monoclonal anti-HMGB1 antibody. (F) The
chemotactic effect of HMGB-1 on primary neutrophils was measured using
a transwell assay system where neutrophils were left to migrate against 50
and 5000 ng/ml HMGB-1, respectively, or 25 ng/ml IL-8 for 2 h. Spontaneous
migration was measured against 1% human serum in PBS (control) (for
details, see Materials and Methods). Values represent means ± s.e.m.
(n = 5) and statistical difference between the control and each respective
sample as determined using the Mann-Whitney test, ∗p < 0.05, ∗∗p < 0.01.
low (50 ng/ml) and high (5000 ng/ml) concentrations induced a
significant neutrophil migration (p < 0.05); almost to the same
extent as the positive control IL-8 (Figure 4F).
HMGB1 is able to form immunostimulatory complexes
in vitro among others with IL-1β (Wahamaa et al., 2011) and
CXCL12 (Schiraldi et al., 2012). To address the potential of
such complexes to form in vivo, severe streptococcal tissue biop-
sies were immunohistochemically stained for CXCL12, IL-1β,
and HMGB1. Our data showed both CXCL12 and IL-1β in the
tissue, and these stainings coincided with areas that had high
HMGB1 expression (Figure 5A). Furthermore, sections were
immunofluorescently stained for HMGB1 in combination with
either CXCL12 or IL-1β. Confocal microscopy analyses revealed
HMGB1 overlapping with IL-1β (yellow areas, Figure 5B) sug-
gesting co-localization. In contrast, this staining pattern was not
noted with HMGB1 and CXCL12. The two proteins appeared in
the same area but did not overlap (Figure 5C).
DISCUSSION
Despite HMGB1’s direct link to necrosis and pro-inflammatory
actions (Harris et al., 2012), there are, to the best of our knowl-
edge, no clinical data to support these mechanistic actions in
necrotizing bacterial infections. Here, we utilized biopsies from
patients with skin and STIs caused by S. pyogenes to assess the
presence of HMGB1 at the local infected site of infections char-
acterized by inflammation and necrosis. Microscopy analyses
revealed HMGB1 in all investigated biopsies, and notably, the
levels correlated with severity of infection. For example, higher
amounts of HMGB1 were found in biopsies from severe STIs as
compared to erysipelas, as well as in the center as compared to
distal site of infection. Per definition, necrotizing fasciitis is char-
acterized by tissue necrosis. Intuitively, the HMGB1 noted at the
tissue site is likely, at least in part, due to passive release from
necrotic cells. However, our vesicular staining pattern of HMGB1
in the infiltrating immune cells indicates that there is also an
active release of HMGB1 predominantly from macrophages,
which likely involves the non-classical vesicle-mediated secretory
pathway (Gardella et al., 2002). This was further strengthened by
in vitro infection of human monocyte-derived macrophages with
S. pyogenes resulted in a release of HMGB1.
In both erysipelas and soft tissue biopsies, infiltrates of neu-
trophils, and macrophages were present. In agreement with our
previous publications (Thulin et al., 2006; Johansson et al., 2009;
Linder et al., 2010), the severe STI biopsies showed massive cellu-
lar infiltrates, substantially higher than in erysipelas. Co-stainings
of cellular markers and HMGB1 revealed a pattern where neu-
trophils were found close to, and in part, surrounding areas with
HMGB1. As HMGB1 has been attributed chemotactic properties
(Venereau et al., 2013), it is tempting to assume that this reflects
a chemotactic response in vivo in infected tissue. A recent report
suggested that the chemotactic effect is concentration dependent,
and that the migration rate of neutrophils may be impaired or
augmented by low or high HMGB1 concentrations, respectively
(Berthelot et al., 2012). In contrast, in this study chemotac-
tic responses were noted both at the low (50 ng/ml) and high
(5000 ng/ml) concentrations. The experimental set-up, including
HMGB1 concentrations, was similar to the previous report, but
the source of HMGB1 differed. Due to limited tissue material,
HMGB1 concentrations could not be directly quantified at the
tissue site. However, our analyses of plasma from patients with
STSS demonstrated HMGB1 levels ranging from 3–39 ng/ml. It
seems likely that the levels at the local tissue site may exceed
those found in circulation, especially considering the high image
analyses values obtained in the tissue biopsies.
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FIGURE 5 | Presence of pro-inflammatory mediators at the local site
of tissue infection. The figure shows representative images of a
snap-frozen cryo-sectioned biopsy, from a patient with severe
streptococcal soft tissue infection. (A) Tissue sections were
immunohistochemically stained for HMGB1, CXCL12, and IL-1β. A control
staining, omitting the primary antibody was also made (control). Bars
indicate 50μm. Snap frozen tissue biopsies were also
immunofluorescently stained for HMGB1 (green) in combination with (B)
IL-1β (red) or (C) CXCL12 (red). Cell nuclei were stained blue with DAPI.
Bars indicate 20μm.
Recently, attention has been given to the function of HMGB1
as an alarmin that forms immunostimulatory complexes with
cytokines and chemotactic factors (Harris et al., 2012; Schiraldi
et al., 2012). These complexes, such as those formed with IL-1β
and CXCL12, have in vitro been shown to be superior in their
inflammatory or chemotactic properties. In our analysis, stain-
ing for IL-1β and CXCL12 showed that both factors are present
in the tissue. Moreover, in the case of IL-1β a substantial overlay
with HMGB1 was noted, providing proof-of-principle support
for formation of these complexes in vivo given the close prox-
imity of the factors in the infected tissue. Such complexes could
theoretically contribute to the tissue destruction by augmenta-
tion of inflammation and leukocytemigration and thus, to disease
pathogenesis.
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